Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 7;113(9):1398-1412.e4.
doi: 10.1016/j.neuron.2025.02.021. Epub 2025 Mar 19.

Ketamine rescues anhedonia by cell-type- and input-specific adaptations in the nucleus accumbens

Affiliations

Ketamine rescues anhedonia by cell-type- and input-specific adaptations in the nucleus accumbens

Federica Lucantonio et al. Neuron. .

Abstract

Ketamine is recognized as a rapid and sustained antidepressant, particularly for major depression unresponsive to conventional treatments. Anhedonia is a common symptom of depression for which ketamine is highly efficacious, but the underlying circuits and synaptic changes are not well understood. Here, we show that the nucleus accumbens (NAc) is essential for ketamine's effect in rescuing anhedonia in mice subjected to chronic stress. Specifically, a single exposure to ketamine rescues stress-induced decreased strength of excitatory synapses on NAc-D1 dopamine receptor-expressing medium spiny neurons (D1-MSNs). Using a cell-specific pharmacology method, we establish the necessity of this synaptic restoration for the sustained therapeutic effects of ketamine on anhedonia. Examining causal sufficiency, artificially increasing excitatory synaptic strength onto D1-MSNs recapitulates the behavioral amelioration induced by ketamine. Finally, we used opto- and chemogenetic approaches to determine the presynaptic origin of the relevant synapses, implicating monosynaptic inputs from the medial prefrontal cortex and ventral hippocampus.

Keywords: AMPA receptors; D1 MSNs; anhedonia; ketamine; nucleus accumbens; prefrontal cortex; stress; sustained antidepressant response; synaptic plasticity; ventral hippocampus.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Update of

References

    1. Malhi GS, and Mann JJ (2018). Depression. Lancet Lond. Engl 392, 2299–2312. 10.1016/S0140-6736(18)31948-2. - DOI - PubMed
    1. Belmaker RH, and Agam G (2008). Major depressive disorder. N. Engl. J. Med 358, 55–68. 10.1056/NEJMra073096. - DOI - PubMed
    1. US Burden of Disease Collaborators, Mokdad AH, Ballestros K, Echko M, Glenn S, Olsen HE, Mullany E, Lee A, Khan AR, Ahmadi A, et al. (2018). The State of US Health, 1990-2016: Burden of Diseases, Injuries, and Risk Factors Among US States. JAMA 319, 1444–1472. 10.1001/jama.2018.0158. - DOI - PMC - PubMed
    1. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163, 1905–1917. 10.1176/ajp.2006.163.11.1905. - DOI - PubMed
    1. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, et al. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163, 28–40. 10.1176/appi.ajp.163.1.28. - DOI - PubMed

LinkOut - more resources